An official website of the State of Maryland.

Maryland.gov Translate

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Prescription Drug Affordability Board

Submit Written Comments

About

Submission windows are open prior to all Board and Stakeholder Council meetings to ensure your feedback is reviewed before any final actions are taken.

CURRENT COMMENT REQUESTS

  • COMMENT PERIOD: The draft Dupixent Dossier was posted on November 10, 2026 and comments will be accepted until November 25, 2026, close of business. Please visit the Draft Dossier tab on the Dupixent cost review study page for more information on how to submit written comments. 

 

ARCHIVE COMMENT REQUESTS

Written Comment Request: Posted 8/31/2026- Comments were due on 9/15/2026. 

In accordance with COMAR 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment for the cost review study process on:

Dupixent (dupilumab)
Drug Brand Name: Dupixent
Active Moiety or Active Ingredient: dupilumab
Application Number: BLA761055
NDC 11s in the Cost Review Study Process - PDF - 86.75 KB

Written Comment Packet - PDF - 4.91 MB of Comments Received. 


AND


Skyrizi (risankizumab)
Drug Brand Name: Skyrizi
Active Moiety or Active Ingredient: risankizumab
Application Number: BLA761105
NDC 11s in the Cost Review Study Process - PDF - 87.53 KB

Written Comment Packet - PDF - 3.51 MBof Comments Received. 

Patient experience and clinician input regarding these drugs are of particular interest but all comments concerning these drug products are encouraged. Written comments were due by the close of business, Tuesday, September 15, 2026.